聚乙二醇多柔比星脂质体及表柔比星在乳腺癌新辅助化疗中的.PDFVIP

·临 床 · 聚乙二醇多柔比星脂质体及表柔比星在乳腺癌新辅助化疗中的应用比较  杨清默，黄于凡，陈双龙，陈文霖，欧阳忠(厦门大学附属第一医院，福建 厦门 361000) 摘要：目的 比较聚乙二醇多柔比星脂质体及表柔比星在乳腺癌新辅助化疗中的疗效及不良反应。方法 回顾性分析2015 年 1 月—12 月行乳腺癌AC-T 或EC-T 新辅助化疗的 146 例患者，其中应用聚乙二醇多柔比星脂质体86 例，应用表柔比 星60 例，分析其临床病理特征、化疗效果及不良反应，并应用Logistic 回归分析影响新辅助化疗疗效的因素。结果 聚 乙二醇多柔比星脂质体组与表柔比星组临床病理特征一致，无统计学差异。2 组新辅助化疗的疗效无统计学差异。HER-2 状态是影响新辅助化疗疗效的主要因素。聚乙二醇多柔比星脂质体组的白细胞降低、消化道反应、脱发及心电图异常等 不良反应较表柔比星组明显减少，而手足综合征则明显增多，具有统计学差异。结论 聚乙二醇多柔比星脂质体与传统 的表柔比星在乳腺癌新辅助化疗中疗效一致。 关键词：聚乙二醇多柔比星脂质体；表柔比星；乳腺癌；新辅助化疗 中图分类号：R965 文献标志码：A 文章编号：1007-7693(2018)08-1221-04 DOI: 10.13748/ki.issn1007-7693.2018.08.023 引用本文：杨清默, 黄于凡, 陈双龙, 等. 聚乙二醇多柔比星脂质体及表柔比星在乳腺癌新辅助化疗中的应用比较[J]. 中 国现代应用药学, 2018, 35(8): 1221-1224. Pegylated Liposomal Doxorubicin and Epirubicin Used in Neoadjuvant Chemotherapy of Breast Cancer YANG Qingmo, HUANG Yufan, CHEN Shuanglong, CHEN Wenlin, OUYANG Zhong(The First Affiliated Hospital of Xiamen University, Xiamen 361003, China) ABSTRACT: OBJECTIVE To investigate the effect of pegylated liposomal doxorubicin and epirubicin used in neoadjuvant chemotherapy of breast cancer. METHODS The 146 patients who accepted neoadjuvant chemotherapy of breast cancer from 2015 January to 2015 december were analyzed, 86 of them received pegylated liposomal doxorubicin, and 60 of them received epirubicin. Compared the clinicopathologic feature, curative effect and untoward effect of drugs between two groups. Logistic regression analysis was used to analyze the factors influencing neoadjuvant chemotherapy. RESULTS Clinicopathologic feature of two groups had no difference. Pegylated liposomal doxorubicin’s curative effect was in accordance with epirubicin’s. The HER-2 state was the main factors affecting curative effect. Pegylat